Justin Thomas, MD
Pulmonary Disease · Rancho Mirage, CANPI 1306065388
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.5%), speaking fees and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Intuitive Surgical at 39.1% of the total. 2025 is the largest year on record at $139,570, more than ten times the $2,185 reported in 2019. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 443 payments — averaging $766.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$133K
- Johnson & Johnson$104K
- Galvanize Therapeutics, Inc$40K
- Ethicon Endo-surgery Inc.$35K
- Medical Device Business Services, Inc.$23K
- Pulmonx Corporation$2K
- plus $3K from 20 others
Across 18 payments — averaging $5539.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson$100K
What the payments were for
- Consulting fees$181,62153%
- Speaking & faculty fees$74,98922%
- Travel & lodging$20,3486%
- Food & beverage$15,6825%
- Education$47,12514%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 191 | $132,944 |
| Johnson & Johnson | 123 | $103,938 |
| Galvanize Therapeutics, Inc | 41 | $40,032 |
| Ethicon Endo-surgery Inc. | 19 | $35,498 |
| Medical Device Business Services, Inc. | 12 | $22,583 |
| Pulmonx Corporation | 22 | $1,637 |
| Noah Medical Corporation | 2 | $1,355 |
| Covidien LP | 4 | $718 |
| Boston Scientific | 2 | $245 |
| GSK | 7 | $135 |
| ERBE USA Inc | 1 | $108 |
| AstraZeneca | 1 | $102 |
| Pinnacle Biologics, Inc | 1 | $99 |
| Sanofi | 3 | $68 |
| Philips North America LLC | 3 | $44 |
| Steris Corporation | 1 | $37 |
| Medtronic | 1 | $35 |
| Insmed, Inc. | 1 | $30 |
| Olympus Corporation Of The Americas | 1 | $26 |
| Grifols USA, LLC | 1 | $23 |
| Baxter Healthcare | 1 | $23 |
| Olympus America Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Electromed, Inc. | 1 | $17 |
| Imbio Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$150,335
- Da Vinci Surgical System$130,976
- ALIYA SYSTEM$39,714
- MONARCH$2,629
- CHARTIS CATHETER$757
- ZEPHYR DELIVERY CATHETER$757
- ZEPHYR ENDOBRONCHIAL VALVE$757
- PULMONX CHARTIS TABLET CONSOLE$757
- superDimension$683
- Pulmonx Endobronchial Valve EBV$352
- ACQUIRE$123
- GENERAL PULMONARY$122
- ErbeCryo2$108
How this compares
$339,775 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aralast NpAlpha-1-Proteinase Inhibitor | 19 | $113,287 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $62,432 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $24,871 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $10,212 |
| Spiriva HandihalerTiotropium Bromide | 17 | $8,475 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,719 |
| Wixela InhubFluticasone Propion/Salmeterol | 39 | $3,640 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,768 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,372 |
| Ipratropium Bromide | 17 | $511 |
| Azithromycin | 12 | $139 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $93 |
| Prednisone | 20 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $135 | $92,022113 claims |
| AstraZenecaSymbicort | $102 | $10,21229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Rancho Mirage
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.